CRL Charles River Laboratories International Inc

Price (delayed)

$149.28

Market cap

$7.63B

P/E Ratio

746.4

Dividend/share

N/A

EPS

$0.2

Enterprise value

$10.16B

Charles River Laboratories, Inc., is an American corporation specializing in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted ...

Highlights
Charles River Laboratories International's debt has decreased by 11% YoY
The price to earnings (P/E) is 189% higher than the last 4 quarters average of 252.9
The EPS has shrunk by 98% YoY and by 98% QoQ

Key stats

What are the main financial stats of CRL
Market
Shares outstanding
51.14M
Market cap
$7.63B
Enterprise value
$10.16B
Valuations
Price to earnings (P/E)
746.4
Price to book (P/B)
2.21
Price to sales (P/S)
1.89
EV/EBIT
46.99
EV/EBITDA
17.58
EV/Sales
2.51
Earnings
Revenue
$4.05B
Gross profit
$1.33B
Operating income
$227.35M
Net income
$22.2M
EBIT
$216.31M
EBITDA
$578.06M
Free cash flow
$501.61M
Per share
EPS
$0.2
EPS diluted
$0.2
Free cash flow per share
$9.76
Book value per share
$67.69
Revenue per share
$78.82
TBVPS
$77.04
Balance sheet
Total assets
$7.53B
Total liabilities
$4.02B
Debt
$2.72B
Equity
$3.46B
Working capital
$408.97M
Liquidity
Debt to equity
0.79
Current ratio
1.41
Quick ratio
0.92
Net debt/EBITDA
4.38
Margins
EBITDA margin
14.3%
Gross margin
32.9%
Net margin
0.5%
Operating margin
5.6%
Efficiency
Return on assets
0.1%
Return on equity
0.3%
Return on invested capital
3.8%
Return on capital employed
3.3%
Return on sales
5.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRL stock price

How has the Charles River Laboratories International stock price performed over time
Intraday
2.25%
1 week
-5.67%
1 month
-9.7%
1 year
-42.98%
YTD
-19.13%
QTD
-0.82%

Financial performance

How have Charles River Laboratories International's revenue and profit performed over time
Revenue
$4.05B
Gross profit
$1.33B
Operating income
$227.35M
Net income
$22.2M
Gross margin
32.9%
Net margin
0.5%
Charles River Laboratories International's net margin has shrunk by 96% YoY and by 95% QoQ
The net income has dropped by 95% year-on-year and by 95% since the previous quarter
CRL's operating income has shrunk by 63% YoY and by 57% QoQ
The operating margin has shrunk by 62% YoY and by 57% QoQ

Growth

What is Charles River Laboratories International's growth rate over time

Valuation

What is Charles River Laboratories International stock price valuation
P/E
746.4
P/B
2.21
P/S
1.89
EV/EBIT
46.99
EV/EBITDA
17.58
EV/Sales
2.51
The price to earnings (P/E) is 189% higher than the last 4 quarters average of 252.9
The EPS has shrunk by 98% YoY and by 98% QoQ
The price to book (P/B) is 54% lower than the 5-year quarterly average of 4.7 and 28% lower than the last 4 quarters average of 3.0
The equity has declined by 8% since the previous quarter and by 3.8% year-on-year
The P/S is 47% lower than the 5-year quarterly average of 3.5 and 31% lower than the last 4 quarters average of 2.7

Efficiency

How efficient is Charles River Laboratories International business performance
The ROE has plunged by 98% YoY and by 97% from the previous quarter
The company's return on assets has shrunk by 98% YoY and by 98% QoQ
The ROS has shrunk by 69% YoY and by 67% QoQ
The company's return on invested capital has shrunk by 69% YoY and by 65% QoQ

Dividends

What is CRL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRL.

Financial health

How did Charles River Laboratories International financials performed over time
The company's total assets is 87% higher than its total liabilities
The total liabilities fell by 11% YoY and by 3.7% QoQ
The quick ratio has declined by 8% year-on-year and by 3.2% since the previous quarter
Charles River Laboratories International's debt is 21% lower than its equity
Charles River Laboratories International's debt has decreased by 11% YoY
The equity has declined by 8% since the previous quarter and by 3.8% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.